Rosenstock et al. [99], in a double-blind, randomized, multicenter, placebo-controlled study, compared the effectiveness, tolerability and safety of TI with that of Technosphere Placebo powder for 12 weeks in 126 patients who had never used insulin but were doing oral therapy against DM2. The gene discussed is INS; the disease is myotonic dystrophy type 2.